샘플 요청 목록

 카트 문의
시장보고서
상품코드
1797243

세계의 피부 진균증 시장

Dermatomycosis
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 389 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 피부 진균증 시장은 2030년까지 166억 달러에 도달

2024년에 141억 달러로 추정되는 세계의 피부 진균증 시장은 2024-2030년의 분석 기간에 CAGR 2.7%로 성장하며, 2030년에는 166억 달러에 달할 것으로 예측됩니다. 이 리포트에서 분석한 부문의 하나인 부신피질 스테로이드는 CAGR 1.8%를 기록하며, 분석 기간 종료시에는 40억 달러에 달할 것으로 예측됩니다. Corticosteroid-sparing Agents(부신피질 스테로이드 절약약) 부문의 성장률은 분석 기간 중 CAGR 3.2%로 추정됩니다.

미국 시장은 38억 달러로 추정, 중국은 CAGR 4.9%로 성장 예측

미국의 피부 진균증 시장은 2024년에 38억 달러로 추정됩니다. 세계 2위의 경제대국인 중국은 2030년까지 32억 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간2024-2030년 CAGR은 4.9%입니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 1.1%와 2.0%로 예측됩니다. 유럽에서는 독일이 CAGR 1.5%로 성장할 것으로 예측됩니다.

세계의 피부 진균증 시장 - 주요 동향과 촉진요인 정리

피부진균증은 왜 전 세계에서 광범위한 피부과적 문제로 대두되고 있는가?

피부진균증은 일반적으로 피부, 모발, 손발톱의 표재성 진균 감염으로 불리며, 세계에서 가장 널리 퍼진 피부과 질환 중 하나로 매년 수억 명이 앓고 있는 것으로 알려져 있습니다. 이 진균 감염증에는 발백선(무좀), 체부백선(백선균), 손발톱무좀(손발톱무좀) 등이 있으며, 온난하고 습한 환경에서 증식하고 특히 열대 및 아열대 지역에 많이 발생합니다. 전 세계 기온 상승, 도시 인구 밀도 증가, 혼잡한 생활환경의 비위생 등이 감염률을 꾸준히 상승시키고 있습니다. 특히 얼굴이나 두피, 손톱 등 눈에 보이는 부위에 발병하면 불편함을 줄 뿐만 아니라 사회적 낙인으로 이어지는 경우가 많습니다. 당뇨병, 비만, 면역 억제 상태, 항생제 및 부신피질 스테로이드의 장기 사용과 같은 요인은 특히 노년층에서 피부진균증에 대한 감수성을 현저하게 증가시킵니다. 또한 헬스장, 수영장, 공동숙박시설 등의 공동이용이 증가하면서 감염의 위험성이 높아지고 있습니다. 피부진균증은 대부분 생명을 위협하는 질환은 아니지만, 효과적인 치료가 이루어지지 않으면 지속적 이고 재발할 가능성이 있으며, 정확한 진단과 장기적인 관리의 필요성이 대두되고 있습니다. 전 세계 많은 지역에서 피부과 의료에 대한 인식이 높아지고 접근성이 개선됨에 따라 일반의약품이나 가정 치료에만 의존하지 않고 의료 서비스를 찾는 사람들이 늘어나고 있습니다. 이러한 피부진균증에 대한 부담이 증가함에 따라 피부과는 공중보건 시스템 및 의약품 개발자들의 관심의 대상이 되고 있습니다.

진단과 치료의 발전은 피부진균증 관리를 어떻게 변화시키고 있는가?

최근 피부과 진단 및 항진균 치료의 발전은 피부진균증 관리를 재구성하고, 치료를 보다 효과적이고, 접근하기 쉽고, 환자에게 적합하게 만들고 있습니다. 임상 검사와 진균 배양에 의한 전통적인 진단은 피부경 검사, 수산화칼륨을 이용한 직접 현미경 검사, 중합효소 연쇄반응(PCR) 분석과 같이 원인균을 보다 빠르고 정확하게 식별할 수 있는 첨단 기술로 보완되고 있습니다. 신속한 진단 툴을 통해 합병증과 재발을 예방하는 데 필수적인 조기 개입이 가능해졌습니다. 치료 측면에서는 새로운 항진균제의 개발로 외용제, 전신제 모두 환자의 예후가 개선되고 치료 기간도 단축되고 있습니다. 테르비나핀과 이트라코나졸과 같은 경구제는 완고한 감염과 광범위한 감염에 널리 사용되며, 새로운 세대의 외용 크림과 스프레이는 국소 증상에 대한 효과적인 선택을 제공합니다. 특히 기존 약물전달이 어려웠던 손발톱이나 두피 감염에 대해는 피부 침투성과 생체 이용률을 높이는 혁신적인 제형이 인기를 끌고 있습니다. 또한 항진균제와 항염증약, 각질용해제를 병용하여 감염뿐만 아니라 가려움증, 비늘 등 관련 증상에도 대응하는 치료법도 보편화되고 있습니다. 또한 특정 항진균제에 대한 내성도 우려되고 있으며, 천연 또는 식물 유래 항진균제, 면역증강제 등 대체 치료법에 대한 연구가 진행되고 있습니다. 원격 피부과 플랫폼과 AI를 활용한 진단 툴은 치료 접근성이 낮은 지역에서 적시에 치료를 제공하기 위해 점점 더 많이 활용되고 있으며, 이를 통해 치료 접근성을 개선하고 있습니다. 이러한 기술과 의약품의 개발로 의료가 현대화되고, 보다 타겟이 명확하고 지속가능한 질병 대책의 길이 열리고 있습니다.

피부진균증 치료의 성장과 범위에 영향을 미치는 시장 동향은 무엇인가?

의료 서비스 제공, 소비자 행동, 의약품 개발의 광범위한 변화를 반영하는 몇 가지 시장 동향이 피부진균증 치료 영역의 확장 및 혁신에 영향을 미치고 있습니다. 중요한 동향 중 하나는 인지도, 편의성, 접근성 향상으로 인해 시판 중인 항진균제에 대한 관심이 높아지고 있다는 점입니다. 소비자들은 자가 진단을 통해 외용 크림, 스프레이, 파우더를 사용하여 초기 치료를 시작하는 경향이 강하며, 증상이 지속되거나 악화되지 않는 한 병원을 찾는 것을 미루는 경우가 많습니다. 이러한 추세에 따라 제조업체들은 브랜드 차별화, 사용하기 쉬운 포장, 감염과 피부 염증에 모두 대응하는 다목적 제형에 대한 투자를 촉진하고 있습니다. 또 다른 중요한 동향은 전자 약국 및 온라인 건강 플랫폼의 부상으로, 원격지나 의료 서비스가 부족한 지역의 소비자들이 항진균제 치료에 더 쉽게 접근할 수 있게 되었습니다는 점입니다. 또한 특히 경증 감염이나 재발성 감염에 대해 합성 의약품을 대체할 수 있는 치료법을 찾는 사람들이 늘어나면서 약초나 자연요법에 대한 관심도 높아지고 있습니다. 한편, 임상 현장에서는 맞춤형 의료의 흐름에 따라 진균의 유형, 감염 부위, 환자의 동반 질환에 따라 보다 맞춤화된 치료 요법이 이루어지고 있습니다. 또한 많은 지역에서 신약 승인에 대한 규제 프레임워크가 강화되고 있으며, 혁신적인 항진균 치료제 시장 진입이 가속화되고 있습니다. 의료기관 부문에서는 병원 및 클리닉이 보다 엄격한 감염 관리 조치를 채택하고 피부진균증 발병을 보다 효율적으로 관리하기 위해 종합적인 진균학 서비스를 제공합니다. 또한 학계와 제약기업과의 협력을 통해 새로운 항진균제, 내성 메커니즘, 숙주와 병원체의 상호작용에 대한 연구가 추진되고 있습니다. 이러한 추세는 피부진균증 관리에 있으며, 유효성, 접근성, 혁신성을 우선시하는 역동적인 시장 환경을 형성하고 있습니다.

전 세계 피부진균증 시장의 주요 성장 촉진요인은 무엇인가?

피부진균증 시장 성장의 원동력은 역학, 임상, 환경, 상업적 요인이 복합적으로 작용하고 있으며, 이러한 요인들이 결합되어 피부진균증이 전 세계에서 영향을 미치고 효과적인 치료에 대한 요구가 증가하고 있음을 지원하고 있습니다. 전 세계에서 기온과 습도가 상승하면서 특히 위생상태가 열악하고 통풍이 잘 되지 않는 도시지역에서 곰팡이가 번식하기 좋은 환경이 조성되고 있습니다. 인구 고령화, 당뇨병, 암, 면역억제 상태의 확산과 같은 인구 통계학적 변화는 진균 감염증, 특히 만성 또는 재발성 진균 감염증에 대한 취약성을 증가시키고 있습니다. 전 세계 여행의 확대, 공동 생활 공간, 체육관, 공공 수영장 이용 증가는 이전에는 위험이 낮다고 여겨졌던 지역에서도 감염률을 높이는 요인으로 작용하고 있습니다. 임상적 측면에서는 의료 전문가와 환자의 인식 개선이 조기 진단과 치료 순응도 향상으로 이어져 처방약과 일반의약품 모두 항진균제 수요를 촉진하고 있습니다. 진단 툴와 치료제의 혁신은 보다 정확하고 효과적인 관리 전략을 가능하게 하고, 제약회사와 생명공학 기업의 투자를 유치하고 있습니다. 또한 E-Commerce와 원격의료의 등장으로 특히 자원이 부족한 환경에서 치료 접근성이 개선되고 환자 참여가 쉬워지고 있습니다. 위생, 예방의학, 피부과 교육에 중점을 둔 정부의 구상도 진균 감염증에 대한 대중의 대응력을 높이는 데 일조하고 있습니다. 주요 시장 진출기업의 탄탄한 유통망과 경쟁력 있는 가격 전략은 항진균 치료제의 세계 보급을 더욱 촉진하고 있습니다. 이러한 다양한 촉진요인이 결합되어 피부진균증 시장은 혁신성, 접근성, 임상 효과를 핵심으로 안정적인 성장을 지속하고 있습니다.

부문

약제 클래스별(부신피질 스테로이드, 부신피질 스테로이드 온존제, 면역억제제, 면역 조절제, 항진균제, 기타 약제), 투여 경로별(경구투여, 비경구투여, 국소 투여, 기타 투여 경로), 최종사용자별(병원 최종사용자, 전문 클리닉 최종사용자, 기타 최종사용자)

조사 대상 기업의 예

  • Almirall, S.A.
  • AmDerma Pharmaceuticals
  • Bausch Health Companies Inc.
  • Bayer AG
  • Cadila Healthcare Ltd.(Zydus)
  • Cipla Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Galderma S.A.
  • Glenmark Pharmaceuticals Ltd.
  • GSK plc(GlaxoSmithKline)
  • Johnson & Johnson
  • Kaken Pharmaceutical Co., Ltd.
  • LEO Pharma A/S
  • Lupin Ltd.
  • Medimetriks Pharmaceuticals
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Sun Pharmaceutical Industries
  • Teva Pharmaceutical Industries

AI 통합

Global Industry Analysts는 유효한 전문가 컨텐츠와 AI 툴에 의해 시장 정보와 경쟁 정보를 변혁하고 있습니다.

Global Industry Analysts는 일반적인 LLM나 업계별 SLM 쿼리에 따르는 대신에, 비디오 기록, 블로그, 검색 엔진 조사, 대량 기업, 제품/서비스, 시장 데이터 등, 전 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수입원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

목차

제1장 조사 방법

제2장 개요

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSA 25.09.02

Global Dermatomycosis Market to Reach US$16.6 Billion by 2030

The global market for Dermatomycosis estimated at US$14.1 Billion in the year 2024, is expected to reach US$16.6 Billion by 2030, growing at a CAGR of 2.7% over the analysis period 2024-2030. Corticosteroids, one of the segments analyzed in the report, is expected to record a 1.8% CAGR and reach US$4.0 Billion by the end of the analysis period. Growth in the Corticosteroid-sparing Agents segment is estimated at 3.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.8 Billion While China is Forecast to Grow at 4.9% CAGR

The Dermatomycosis market in the U.S. is estimated at US$3.8 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$3.2 Billion by the year 2030 trailing a CAGR of 4.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.1% and 2.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.5% CAGR.

Global Dermatomycosis Market - Key Trends & Drivers Summarized

Why Is Dermatomycosis Emerging as a Widespread Dermatological Challenge Globally?

Dermatomycosis, commonly referred to as superficial fungal infection of the skin, hair, or nails, is emerging as one of the most prevalent dermatological conditions worldwide, affecting hundreds of millions of people annually. This group of fungal infections, including tinea pedis (athlete’s foot), tinea corporis (ringworm), and onychomycosis (nail fungus), thrives in warm, humid environments and is particularly common in tropical and subtropical regions. Rising global temperatures, increasing urban density, and poor hygiene in crowded living conditions are all contributing to a steady rise in infection rates. The condition is not only a source of discomfort but also often leads to social stigma, particularly when it affects visible parts of the body such as the face, scalp, or nails. Factors such as diabetes, obesity, immunosuppressive conditions, and long-term use of antibiotics or corticosteroids significantly increase susceptibility to dermatomycosis, especially among elderly populations. In addition, the increased use of communal facilities like gyms, swimming pools, and shared accommodations has heightened the risk of transmission. Despite being non-life-threatening in most cases, dermatomycosis can be persistent and recurrent if not treated effectively, leading to a growing need for accurate diagnosis and long-term management. As awareness rises and access to dermatological services improves in many parts of the world, more individuals are seeking medical treatment rather than relying solely on over-the-counter remedies or home-based interventions. This growing burden of dermatomycosis is placing it firmly on the radar of public health systems and pharmaceutical developers alike.

How Are Advancements in Diagnosis and Treatment Reshaping the Management of Dermatomycosis?

Recent advancements in dermatological diagnostics and antifungal therapies are reshaping the management of dermatomycosis, making treatments more effective, accessible, and patient-specific. Traditional diagnosis through clinical examination and fungal culture is increasingly being supplemented by more advanced techniques such as dermoscopy, direct microscopic examination with potassium hydroxide, and polymerase chain reaction (PCR) assays, which allow for faster and more accurate identification of causative organisms. Rapid diagnostic tools have enabled earlier intervention, which is critical in preventing complications and recurrence. On the treatment front, the development of newer antifungal agents, both topical and systemic, is improving patient outcomes and reducing the duration of treatment. Oral agents like terbinafine and itraconazole are widely used for stubborn or widespread infections, while new-generation topical creams and sprays provide effective options for localized conditions. Innovative formulations that enhance skin penetration and bioavailability are gaining popularity, especially for nail and scalp infections where drug delivery has traditionally been a challenge. In addition, combination therapies that include antifungal agents with anti-inflammatory or keratolytic ingredients are becoming common to address both the infection and associated symptoms like itching and scaling. Resistance to certain antifungal drugs is also a growing concern, prompting research into alternative treatments, including natural or plant-derived antifungals and immune-boosting agents. Teledermatology platforms and AI-powered diagnostic tools are increasingly being utilized to deliver timely care in underserved areas, thereby improving access to treatment. These technological and pharmaceutical developments are modernizing dermatomycosis care and paving the way for more targeted and sustainable approaches to disease control.

What Market Trends Are Influencing the Growth and Scope of Dermatomycosis Treatments?

Several market trends are influencing the expansion and innovation within the dermatomycosis treatment space, reflecting broader shifts in healthcare delivery, consumer behavior, and pharmaceutical development. One significant trend is the growing inclination toward over-the-counter antifungal medications, driven by greater awareness, convenience, and accessibility. Consumers are more likely to self-diagnose and begin initial treatment using topical creams, sprays, or powders, often delaying clinical consultation unless symptoms persist or worsen. This trend has prompted manufacturers to invest in brand differentiation, user-friendly packaging, and multipurpose formulations that address both infection and skin irritation. Another key trend is the rise of e-pharmacies and online health platforms, which has made antifungal treatments more accessible to consumers in remote or underserved locations. There is also increasing interest in herbal and natural remedies, as more individuals seek alternatives to synthetic pharmaceuticals, particularly for mild or recurrent infections. Meanwhile, in clinical settings, the trend toward personalized medicine is leading to more tailored treatment regimens based on fungal species, site of infection, and patient comorbidities. Regulatory frameworks in many regions are becoming more supportive of novel drug approvals, allowing for faster market entry of innovative antifungal therapies. In the institutional segment, hospitals and clinics are adopting stricter infection control measures and offering comprehensive mycology services to manage dermatomycosis outbreaks more efficiently. Partnerships between academic institutions and pharmaceutical companies are driving research into new antifungal agents, resistance mechanisms, and host-pathogen interactions. These trends are collectively shaping a dynamic market environment that prioritizes effectiveness, accessibility, and innovation in managing dermatomycosis.

What Are the Primary Drivers Behind the Global Growth of the Dermatomycosis Market?

The growth in the dermatomycosis market is driven by a combination of epidemiological, clinical, environmental, and commercial factors that together underline the condition’s global impact and the expanding need for effective treatments. Rising global temperatures and humidity levels are creating more favorable environments for fungal proliferation, especially in urban areas with poor sanitation and limited ventilation. Demographic shifts such as aging populations and rising prevalence of diabetes, cancer, and immunosuppressive conditions are increasing vulnerability to fungal infections, particularly chronic or recurrent forms of dermatomycosis. The expansion of global travel and increased use of communal living spaces, gyms, and public pools are contributing to higher transmission rates, even in regions previously considered low-risk. From a clinical standpoint, improved awareness among healthcare professionals and patients is leading to earlier diagnosis and better treatment adherence, fueling demand for both prescription and over-the-counter antifungal products. Technological innovations in diagnostic tools and therapeutic formulations are enabling more precise and effective management strategies, attracting investment from pharmaceutical and biotech companies. Additionally, the rise of e-commerce and telehealth is improving treatment access and facilitating patient engagement, especially in low-resource settings. Government initiatives focused on hygiene, preventive care, and dermatological education are also playing a role in increasing public responsiveness to fungal infections. The presence of robust distribution networks and competitive pricing strategies by key market players further supports the global proliferation of antifungal treatments. Together, these diverse drivers are ensuring that the dermatomycosis market continues to grow steadily, with innovation, accessibility, and clinical effectiveness at its core.

SCOPE OF STUDY:

The report analyzes the Dermatomycosis market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Class (Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals, Other Drugs); Administration Route (Oral Administration, Parenteral Administration, Topical Administration, Other Administration Routes); End-User (Hospitals End-User, Specialty Clinics End-User, Other End-Users)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

  • Almirall, S.A.
  • AmDerma Pharmaceuticals
  • Bausch Health Companies Inc.
  • Bayer AG
  • Cadila Healthcare Ltd. (Zydus)
  • Cipla Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Galderma S.A.
  • Glenmark Pharmaceuticals Ltd.
  • GSK plc (GlaxoSmithKline)
  • Johnson & Johnson
  • Kaken Pharmaceutical Co., Ltd.
  • LEO Pharma A/S
  • Lupin Ltd.
  • Medimetriks Pharmaceuticals
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Sun Pharmaceutical Industries
  • Teva Pharmaceutical Industries

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Dermatomycosis - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Incidence of Superficial Fungal Infections Throws the Spotlight on Dermatomycosis Treatments
    • Increasing Prevalence in Tropical and Humid Regions Expands the Addressable Market for Antifungal Therapies
    • Growing Awareness of Skin Health and Hygiene Drives Early Diagnosis and Over-the-Counter Treatment Uptake
    • Expanding Geriatric and Immunocompromised Populations Strengthens the Business Case for Chronic Infection Management
    • Advancements in Topical and Systemic Antifungal Formulations Propel Market Innovation
    • Availability of Combination Therapies Accelerates Demand for Multifunctional Treatment Regimens
    • Antifungal Resistance Concerns Create Opportunities for Novel Drug Classes and Research Investments
    • E-Commerce and Online Pharmacies Spur Growth in Direct-to-Consumer Dermatology Products
    • Outreach and Awareness Campaigns by Health Agencies Drive Prevention and Early Intervention
    • Rising Demand for Natural and Herbal Antifungals Opens New Product Development Channels
    • Climate Change and Global Travel Trends Contribute to the Geographic Spread of Dermatomycosis
    • Integration of AI and Digital Diagnostics Drives Early Detection and Tailored Treatment Plans
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Dermatomycosis Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Dermatomycosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Dermatomycosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Dermatomycosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Corticosteroids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Corticosteroid-sparing Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Corticosteroid-sparing Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Corticosteroid-sparing Agents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Immunosuppressive by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Immunosuppressive by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Immunosuppressive by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Immunomodulator by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Immunomodulator by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Immunomodulator by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Antifungals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Antifungals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Antifungals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Other Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Other Administration Routes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Other Administration Routes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Other Administration Routes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Oral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Oral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: World 16-Year Perspective for Oral Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Parenteral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Parenteral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: World 16-Year Perspective for Parenteral Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Topical Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Topical Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: World 16-Year Perspective for Topical Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Hospitals End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Hospitals End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: World 16-Year Perspective for Hospitals End-User by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Specialty Clinics End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Specialty Clinics End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: World 16-Year Perspective for Specialty Clinics End-User by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 41: World Recent Past, Current & Future Analysis for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 42: World Historic Review for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: World 16-Year Perspective for Other End-Users by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Dermatomycosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 44: USA Recent Past, Current & Future Analysis for Dermatomycosis by Drug Class - Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Dermatomycosis by Drug Class - Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: USA 16-Year Perspective for Dermatomycosis by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs for the Years 2014, 2025 & 2030
    • TABLE 47: USA Recent Past, Current & Future Analysis for Dermatomycosis by Administration Route - Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: USA Historic Review for Dermatomycosis by Administration Route - Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: USA 16-Year Perspective for Dermatomycosis by Administration Route - Percentage Breakdown of Value Sales for Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration for the Years 2014, 2025 & 2030
    • TABLE 50: USA Recent Past, Current & Future Analysis for Dermatomycosis by End-user - Hospitals End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: USA Historic Review for Dermatomycosis by End-user - Hospitals End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: USA 16-Year Perspective for Dermatomycosis by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 53: Canada Recent Past, Current & Future Analysis for Dermatomycosis by Drug Class - Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Canada Historic Review for Dermatomycosis by Drug Class - Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: Canada 16-Year Perspective for Dermatomycosis by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs for the Years 2014, 2025 & 2030
    • TABLE 56: Canada Recent Past, Current & Future Analysis for Dermatomycosis by Administration Route - Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Canada Historic Review for Dermatomycosis by Administration Route - Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: Canada 16-Year Perspective for Dermatomycosis by Administration Route - Percentage Breakdown of Value Sales for Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration for the Years 2014, 2025 & 2030
    • TABLE 59: Canada Recent Past, Current & Future Analysis for Dermatomycosis by End-user - Hospitals End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Canada Historic Review for Dermatomycosis by End-user - Hospitals End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: Canada 16-Year Perspective for Dermatomycosis by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • JAPAN
    • Dermatomycosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 62: Japan Recent Past, Current & Future Analysis for Dermatomycosis by Drug Class - Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Japan Historic Review for Dermatomycosis by Drug Class - Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: Japan 16-Year Perspective for Dermatomycosis by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs for the Years 2014, 2025 & 2030
    • TABLE 65: Japan Recent Past, Current & Future Analysis for Dermatomycosis by Administration Route - Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Japan Historic Review for Dermatomycosis by Administration Route - Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: Japan 16-Year Perspective for Dermatomycosis by Administration Route - Percentage Breakdown of Value Sales for Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration for the Years 2014, 2025 & 2030
    • TABLE 68: Japan Recent Past, Current & Future Analysis for Dermatomycosis by End-user - Hospitals End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Japan Historic Review for Dermatomycosis by End-user - Hospitals End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: Japan 16-Year Perspective for Dermatomycosis by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • CHINA
    • Dermatomycosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 71: China Recent Past, Current & Future Analysis for Dermatomycosis by Drug Class - Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: China Historic Review for Dermatomycosis by Drug Class - Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: China 16-Year Perspective for Dermatomycosis by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs for the Years 2014, 2025 & 2030
    • TABLE 74: China Recent Past, Current & Future Analysis for Dermatomycosis by Administration Route - Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: China Historic Review for Dermatomycosis by Administration Route - Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: China 16-Year Perspective for Dermatomycosis by Administration Route - Percentage Breakdown of Value Sales for Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration for the Years 2014, 2025 & 2030
    • TABLE 77: China Recent Past, Current & Future Analysis for Dermatomycosis by End-user - Hospitals End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: China Historic Review for Dermatomycosis by End-user - Hospitals End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: China 16-Year Perspective for Dermatomycosis by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • EUROPE
    • Dermatomycosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Dermatomycosis by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Dermatomycosis by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: Europe 16-Year Perspective for Dermatomycosis by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 83: Europe Recent Past, Current & Future Analysis for Dermatomycosis by Drug Class - Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Europe Historic Review for Dermatomycosis by Drug Class - Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: Europe 16-Year Perspective for Dermatomycosis by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs for the Years 2014, 2025 & 2030
    • TABLE 86: Europe Recent Past, Current & Future Analysis for Dermatomycosis by Administration Route - Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Europe Historic Review for Dermatomycosis by Administration Route - Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: Europe 16-Year Perspective for Dermatomycosis by Administration Route - Percentage Breakdown of Value Sales for Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration for the Years 2014, 2025 & 2030
    • TABLE 89: Europe Recent Past, Current & Future Analysis for Dermatomycosis by End-user - Hospitals End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Europe Historic Review for Dermatomycosis by End-user - Hospitals End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: Europe 16-Year Perspective for Dermatomycosis by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • FRANCE
    • Dermatomycosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 92: France Recent Past, Current & Future Analysis for Dermatomycosis by Drug Class - Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: France Historic Review for Dermatomycosis by Drug Class - Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: France 16-Year Perspective for Dermatomycosis by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs for the Years 2014, 2025 & 2030
    • TABLE 95: France Recent Past, Current & Future Analysis for Dermatomycosis by Administration Route - Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: France Historic Review for Dermatomycosis by Administration Route - Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: France 16-Year Perspective for Dermatomycosis by Administration Route - Percentage Breakdown of Value Sales for Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration for the Years 2014, 2025 & 2030
    • TABLE 98: France Recent Past, Current & Future Analysis for Dermatomycosis by End-user - Hospitals End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: France Historic Review for Dermatomycosis by End-user - Hospitals End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: France 16-Year Perspective for Dermatomycosis by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • GERMANY
    • Dermatomycosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 101: Germany Recent Past, Current & Future Analysis for Dermatomycosis by Drug Class - Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Germany Historic Review for Dermatomycosis by Drug Class - Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: Germany 16-Year Perspective for Dermatomycosis by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs for the Years 2014, 2025 & 2030
    • TABLE 104: Germany Recent Past, Current & Future Analysis for Dermatomycosis by Administration Route - Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Germany Historic Review for Dermatomycosis by Administration Route - Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: Germany 16-Year Perspective for Dermatomycosis by Administration Route - Percentage Breakdown of Value Sales for Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration for the Years 2014, 2025 & 2030
    • TABLE 107: Germany Recent Past, Current & Future Analysis for Dermatomycosis by End-user - Hospitals End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Germany Historic Review for Dermatomycosis by End-user - Hospitals End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: Germany 16-Year Perspective for Dermatomycosis by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 110: Italy Recent Past, Current & Future Analysis for Dermatomycosis by Drug Class - Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Italy Historic Review for Dermatomycosis by Drug Class - Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 112: Italy 16-Year Perspective for Dermatomycosis by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs for the Years 2014, 2025 & 2030
    • TABLE 113: Italy Recent Past, Current & Future Analysis for Dermatomycosis by Administration Route - Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Italy Historic Review for Dermatomycosis by Administration Route - Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 115: Italy 16-Year Perspective for Dermatomycosis by Administration Route - Percentage Breakdown of Value Sales for Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration for the Years 2014, 2025 & 2030
    • TABLE 116: Italy Recent Past, Current & Future Analysis for Dermatomycosis by End-user - Hospitals End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Italy Historic Review for Dermatomycosis by End-user - Hospitals End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 118: Italy 16-Year Perspective for Dermatomycosis by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Dermatomycosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 119: UK Recent Past, Current & Future Analysis for Dermatomycosis by Drug Class - Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: UK Historic Review for Dermatomycosis by Drug Class - Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 121: UK 16-Year Perspective for Dermatomycosis by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs for the Years 2014, 2025 & 2030
    • TABLE 122: UK Recent Past, Current & Future Analysis for Dermatomycosis by Administration Route - Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: UK Historic Review for Dermatomycosis by Administration Route - Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 124: UK 16-Year Perspective for Dermatomycosis by Administration Route - Percentage Breakdown of Value Sales for Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration for the Years 2014, 2025 & 2030
    • TABLE 125: UK Recent Past, Current & Future Analysis for Dermatomycosis by End-user - Hospitals End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: UK Historic Review for Dermatomycosis by End-user - Hospitals End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 127: UK 16-Year Perspective for Dermatomycosis by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 128: Spain Recent Past, Current & Future Analysis for Dermatomycosis by Drug Class - Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Spain Historic Review for Dermatomycosis by Drug Class - Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 130: Spain 16-Year Perspective for Dermatomycosis by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs for the Years 2014, 2025 & 2030
    • TABLE 131: Spain Recent Past, Current & Future Analysis for Dermatomycosis by Administration Route - Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Spain Historic Review for Dermatomycosis by Administration Route - Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 133: Spain 16-Year Perspective for Dermatomycosis by Administration Route - Percentage Breakdown of Value Sales for Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration for the Years 2014, 2025 & 2030
    • TABLE 134: Spain Recent Past, Current & Future Analysis for Dermatomycosis by End-user - Hospitals End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Spain Historic Review for Dermatomycosis by End-user - Hospitals End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 136: Spain 16-Year Perspective for Dermatomycosis by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 137: Russia Recent Past, Current & Future Analysis for Dermatomycosis by Drug Class - Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Russia Historic Review for Dermatomycosis by Drug Class - Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 139: Russia 16-Year Perspective for Dermatomycosis by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs for the Years 2014, 2025 & 2030
    • TABLE 140: Russia Recent Past, Current & Future Analysis for Dermatomycosis by Administration Route - Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Russia Historic Review for Dermatomycosis by Administration Route - Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 142: Russia 16-Year Perspective for Dermatomycosis by Administration Route - Percentage Breakdown of Value Sales for Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration for the Years 2014, 2025 & 2030
    • TABLE 143: Russia Recent Past, Current & Future Analysis for Dermatomycosis by End-user - Hospitals End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Russia Historic Review for Dermatomycosis by End-user - Hospitals End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 145: Russia 16-Year Perspective for Dermatomycosis by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Dermatomycosis by Drug Class - Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Rest of Europe Historic Review for Dermatomycosis by Drug Class - Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 148: Rest of Europe 16-Year Perspective for Dermatomycosis by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs for the Years 2014, 2025 & 2030
    • TABLE 149: Rest of Europe Recent Past, Current & Future Analysis for Dermatomycosis by Administration Route - Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Rest of Europe Historic Review for Dermatomycosis by Administration Route - Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 151: Rest of Europe 16-Year Perspective for Dermatomycosis by Administration Route - Percentage Breakdown of Value Sales for Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration for the Years 2014, 2025 & 2030
    • TABLE 152: Rest of Europe Recent Past, Current & Future Analysis for Dermatomycosis by End-user - Hospitals End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Rest of Europe Historic Review for Dermatomycosis by End-user - Hospitals End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 154: Rest of Europe 16-Year Perspective for Dermatomycosis by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Dermatomycosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Dermatomycosis by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for Dermatomycosis by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 157: Asia-Pacific 16-Year Perspective for Dermatomycosis by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Dermatomycosis by Drug Class - Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Asia-Pacific Historic Review for Dermatomycosis by Drug Class - Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 160: Asia-Pacific 16-Year Perspective for Dermatomycosis by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs for the Years 2014, 2025 & 2030
    • TABLE 161: Asia-Pacific Recent Past, Current & Future Analysis for Dermatomycosis by Administration Route - Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Asia-Pacific Historic Review for Dermatomycosis by Administration Route - Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 163: Asia-Pacific 16-Year Perspective for Dermatomycosis by Administration Route - Percentage Breakdown of Value Sales for Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration for the Years 2014, 2025 & 2030
    • TABLE 164: Asia-Pacific Recent Past, Current & Future Analysis for Dermatomycosis by End-user - Hospitals End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Asia-Pacific Historic Review for Dermatomycosis by End-user - Hospitals End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 166: Asia-Pacific 16-Year Perspective for Dermatomycosis by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Dermatomycosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 167: Australia Recent Past, Current & Future Analysis for Dermatomycosis by Drug Class - Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Australia Historic Review for Dermatomycosis by Drug Class - Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 169: Australia 16-Year Perspective for Dermatomycosis by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs for the Years 2014, 2025 & 2030
    • TABLE 170: Australia Recent Past, Current & Future Analysis for Dermatomycosis by Administration Route - Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Australia Historic Review for Dermatomycosis by Administration Route - Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 172: Australia 16-Year Perspective for Dermatomycosis by Administration Route - Percentage Breakdown of Value Sales for Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration for the Years 2014, 2025 & 2030
    • TABLE 173: Australia Recent Past, Current & Future Analysis for Dermatomycosis by End-user - Hospitals End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Australia Historic Review for Dermatomycosis by End-user - Hospitals End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 175: Australia 16-Year Perspective for Dermatomycosis by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • INDIA
    • Dermatomycosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 176: India Recent Past, Current & Future Analysis for Dermatomycosis by Drug Class - Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: India Historic Review for Dermatomycosis by Drug Class - Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 178: India 16-Year Perspective for Dermatomycosis by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs for the Years 2014, 2025 & 2030
    • TABLE 179: India Recent Past, Current & Future Analysis for Dermatomycosis by Administration Route - Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: India Historic Review for Dermatomycosis by Administration Route - Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 181: India 16-Year Perspective for Dermatomycosis by Administration Route - Percentage Breakdown of Value Sales for Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration for the Years 2014, 2025 & 2030
    • TABLE 182: India Recent Past, Current & Future Analysis for Dermatomycosis by End-user - Hospitals End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: India Historic Review for Dermatomycosis by End-user - Hospitals End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 184: India 16-Year Perspective for Dermatomycosis by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 185: South Korea Recent Past, Current & Future Analysis for Dermatomycosis by Drug Class - Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: South Korea Historic Review for Dermatomycosis by Drug Class - Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 187: South Korea 16-Year Perspective for Dermatomycosis by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs for the Years 2014, 2025 & 2030
    • TABLE 188: South Korea Recent Past, Current & Future Analysis for Dermatomycosis by Administration Route - Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: South Korea Historic Review for Dermatomycosis by Administration Route - Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 190: South Korea 16-Year Perspective for Dermatomycosis by Administration Route - Percentage Breakdown of Value Sales for Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration for the Years 2014, 2025 & 2030
    • TABLE 191: South Korea Recent Past, Current & Future Analysis for Dermatomycosis by End-user - Hospitals End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: South Korea Historic Review for Dermatomycosis by End-user - Hospitals End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 193: South Korea 16-Year Perspective for Dermatomycosis by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Dermatomycosis by Drug Class - Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Asia-Pacific Historic Review for Dermatomycosis by Drug Class - Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 196: Rest of Asia-Pacific 16-Year Perspective for Dermatomycosis by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs for the Years 2014, 2025 & 2030
    • TABLE 197: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Dermatomycosis by Administration Route - Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Asia-Pacific Historic Review for Dermatomycosis by Administration Route - Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 199: Rest of Asia-Pacific 16-Year Perspective for Dermatomycosis by Administration Route - Percentage Breakdown of Value Sales for Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration for the Years 2014, 2025 & 2030
    • TABLE 200: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Dermatomycosis by End-user - Hospitals End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Asia-Pacific Historic Review for Dermatomycosis by End-user - Hospitals End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 202: Rest of Asia-Pacific 16-Year Perspective for Dermatomycosis by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Dermatomycosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 203: Latin America Recent Past, Current & Future Analysis for Dermatomycosis by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 204: Latin America Historic Review for Dermatomycosis by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 205: Latin America 16-Year Perspective for Dermatomycosis by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 206: Latin America Recent Past, Current & Future Analysis for Dermatomycosis by Drug Class - Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Latin America Historic Review for Dermatomycosis by Drug Class - Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 208: Latin America 16-Year Perspective for Dermatomycosis by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs for the Years 2014, 2025 & 2030
    • TABLE 209: Latin America Recent Past, Current & Future Analysis for Dermatomycosis by Administration Route - Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Latin America Historic Review for Dermatomycosis by Administration Route - Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 211: Latin America 16-Year Perspective for Dermatomycosis by Administration Route - Percentage Breakdown of Value Sales for Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration for the Years 2014, 2025 & 2030
    • TABLE 212: Latin America Recent Past, Current & Future Analysis for Dermatomycosis by End-user - Hospitals End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Latin America Historic Review for Dermatomycosis by End-user - Hospitals End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 214: Latin America 16-Year Perspective for Dermatomycosis by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 215: Argentina Recent Past, Current & Future Analysis for Dermatomycosis by Drug Class - Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Argentina Historic Review for Dermatomycosis by Drug Class - Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 217: Argentina 16-Year Perspective for Dermatomycosis by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs for the Years 2014, 2025 & 2030
    • TABLE 218: Argentina Recent Past, Current & Future Analysis for Dermatomycosis by Administration Route - Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Argentina Historic Review for Dermatomycosis by Administration Route - Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 220: Argentina 16-Year Perspective for Dermatomycosis by Administration Route - Percentage Breakdown of Value Sales for Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration for the Years 2014, 2025 & 2030
    • TABLE 221: Argentina Recent Past, Current & Future Analysis for Dermatomycosis by End-user - Hospitals End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Argentina Historic Review for Dermatomycosis by End-user - Hospitals End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 223: Argentina 16-Year Perspective for Dermatomycosis by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 224: Brazil Recent Past, Current & Future Analysis for Dermatomycosis by Drug Class - Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Brazil Historic Review for Dermatomycosis by Drug Class - Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 226: Brazil 16-Year Perspective for Dermatomycosis by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs for the Years 2014, 2025 & 2030
    • TABLE 227: Brazil Recent Past, Current & Future Analysis for Dermatomycosis by Administration Route - Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Brazil Historic Review for Dermatomycosis by Administration Route - Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 229: Brazil 16-Year Perspective for Dermatomycosis by Administration Route - Percentage Breakdown of Value Sales for Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration for the Years 2014, 2025 & 2030
    • TABLE 230: Brazil Recent Past, Current & Future Analysis for Dermatomycosis by End-user - Hospitals End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Brazil Historic Review for Dermatomycosis by End-user - Hospitals End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 232: Brazil 16-Year Perspective for Dermatomycosis by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 233: Mexico Recent Past, Current & Future Analysis for Dermatomycosis by Drug Class - Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Mexico Historic Review for Dermatomycosis by Drug Class - Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 235: Mexico 16-Year Perspective for Dermatomycosis by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs for the Years 2014, 2025 & 2030
    • TABLE 236: Mexico Recent Past, Current & Future Analysis for Dermatomycosis by Administration Route - Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Mexico Historic Review for Dermatomycosis by Administration Route - Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 238: Mexico 16-Year Perspective for Dermatomycosis by Administration Route - Percentage Breakdown of Value Sales for Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration for the Years 2014, 2025 & 2030
    • TABLE 239: Mexico Recent Past, Current & Future Analysis for Dermatomycosis by End-user - Hospitals End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Mexico Historic Review for Dermatomycosis by End-user - Hospitals End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 241: Mexico 16-Year Perspective for Dermatomycosis by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Dermatomycosis by Drug Class - Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Rest of Latin America Historic Review for Dermatomycosis by Drug Class - Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 244: Rest of Latin America 16-Year Perspective for Dermatomycosis by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs for the Years 2014, 2025 & 2030
    • TABLE 245: Rest of Latin America Recent Past, Current & Future Analysis for Dermatomycosis by Administration Route - Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Rest of Latin America Historic Review for Dermatomycosis by Administration Route - Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 247: Rest of Latin America 16-Year Perspective for Dermatomycosis by Administration Route - Percentage Breakdown of Value Sales for Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration for the Years 2014, 2025 & 2030
    • TABLE 248: Rest of Latin America Recent Past, Current & Future Analysis for Dermatomycosis by End-user - Hospitals End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Rest of Latin America Historic Review for Dermatomycosis by End-user - Hospitals End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 250: Rest of Latin America 16-Year Perspective for Dermatomycosis by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Dermatomycosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 251: Middle East Recent Past, Current & Future Analysis for Dermatomycosis by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 252: Middle East Historic Review for Dermatomycosis by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 253: Middle East 16-Year Perspective for Dermatomycosis by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 254: Middle East Recent Past, Current & Future Analysis for Dermatomycosis by Drug Class - Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Middle East Historic Review for Dermatomycosis by Drug Class - Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 256: Middle East 16-Year Perspective for Dermatomycosis by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs for the Years 2014, 2025 & 2030
    • TABLE 257: Middle East Recent Past, Current & Future Analysis for Dermatomycosis by Administration Route - Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Middle East Historic Review for Dermatomycosis by Administration Route - Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 259: Middle East 16-Year Perspective for Dermatomycosis by Administration Route - Percentage Breakdown of Value Sales for Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration for the Years 2014, 2025 & 2030
    • TABLE 260: Middle East Recent Past, Current & Future Analysis for Dermatomycosis by End-user - Hospitals End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Middle East Historic Review for Dermatomycosis by End-user - Hospitals End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 262: Middle East 16-Year Perspective for Dermatomycosis by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 263: Iran Recent Past, Current & Future Analysis for Dermatomycosis by Drug Class - Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Iran Historic Review for Dermatomycosis by Drug Class - Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 265: Iran 16-Year Perspective for Dermatomycosis by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs for the Years 2014, 2025 & 2030
    • TABLE 266: Iran Recent Past, Current & Future Analysis for Dermatomycosis by Administration Route - Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Iran Historic Review for Dermatomycosis by Administration Route - Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 268: Iran 16-Year Perspective for Dermatomycosis by Administration Route - Percentage Breakdown of Value Sales for Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration for the Years 2014, 2025 & 2030
    • TABLE 269: Iran Recent Past, Current & Future Analysis for Dermatomycosis by End-user - Hospitals End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Iran Historic Review for Dermatomycosis by End-user - Hospitals End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 271: Iran 16-Year Perspective for Dermatomycosis by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 272: Israel Recent Past, Current & Future Analysis for Dermatomycosis by Drug Class - Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Israel Historic Review for Dermatomycosis by Drug Class - Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 274: Israel 16-Year Perspective for Dermatomycosis by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs for the Years 2014, 2025 & 2030
    • TABLE 275: Israel Recent Past, Current & Future Analysis for Dermatomycosis by Administration Route - Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Israel Historic Review for Dermatomycosis by Administration Route - Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 277: Israel 16-Year Perspective for Dermatomycosis by Administration Route - Percentage Breakdown of Value Sales for Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration for the Years 2014, 2025 & 2030
    • TABLE 278: Israel Recent Past, Current & Future Analysis for Dermatomycosis by End-user - Hospitals End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Israel Historic Review for Dermatomycosis by End-user - Hospitals End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 280: Israel 16-Year Perspective for Dermatomycosis by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Dermatomycosis by Drug Class - Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Saudi Arabia Historic Review for Dermatomycosis by Drug Class - Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 283: Saudi Arabia 16-Year Perspective for Dermatomycosis by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs for the Years 2014, 2025 & 2030
    • TABLE 284: Saudi Arabia Recent Past, Current & Future Analysis for Dermatomycosis by Administration Route - Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Saudi Arabia Historic Review for Dermatomycosis by Administration Route - Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 286: Saudi Arabia 16-Year Perspective for Dermatomycosis by Administration Route - Percentage Breakdown of Value Sales for Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration for the Years 2014, 2025 & 2030
    • TABLE 287: Saudi Arabia Recent Past, Current & Future Analysis for Dermatomycosis by End-user - Hospitals End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Saudi Arabia Historic Review for Dermatomycosis by End-user - Hospitals End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 289: Saudi Arabia 16-Year Perspective for Dermatomycosis by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 290: UAE Recent Past, Current & Future Analysis for Dermatomycosis by Drug Class - Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: UAE Historic Review for Dermatomycosis by Drug Class - Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 292: UAE 16-Year Perspective for Dermatomycosis by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs for the Years 2014, 2025 & 2030
    • TABLE 293: UAE Recent Past, Current & Future Analysis for Dermatomycosis by Administration Route - Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: UAE Historic Review for Dermatomycosis by Administration Route - Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 295: UAE 16-Year Perspective for Dermatomycosis by Administration Route - Percentage Breakdown of Value Sales for Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration for the Years 2014, 2025 & 2030
    • TABLE 296: UAE Recent Past, Current & Future Analysis for Dermatomycosis by End-user - Hospitals End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: UAE Historic Review for Dermatomycosis by End-user - Hospitals End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 298: UAE 16-Year Perspective for Dermatomycosis by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Dermatomycosis by Drug Class - Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Rest of Middle East Historic Review for Dermatomycosis by Drug Class - Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 301: Rest of Middle East 16-Year Perspective for Dermatomycosis by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs for the Years 2014, 2025 & 2030
    • TABLE 302: Rest of Middle East Recent Past, Current & Future Analysis for Dermatomycosis by Administration Route - Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Rest of Middle East Historic Review for Dermatomycosis by Administration Route - Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 304: Rest of Middle East 16-Year Perspective for Dermatomycosis by Administration Route - Percentage Breakdown of Value Sales for Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration for the Years 2014, 2025 & 2030
    • TABLE 305: Rest of Middle East Recent Past, Current & Future Analysis for Dermatomycosis by End-user - Hospitals End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Rest of Middle East Historic Review for Dermatomycosis by End-user - Hospitals End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 307: Rest of Middle East 16-Year Perspective for Dermatomycosis by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • AFRICA
    • Dermatomycosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 308: Africa Recent Past, Current & Future Analysis for Dermatomycosis by Drug Class - Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 309: Africa Historic Review for Dermatomycosis by Drug Class - Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 310: Africa 16-Year Perspective for Dermatomycosis by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs for the Years 2014, 2025 & 2030
    • TABLE 311: Africa Recent Past, Current & Future Analysis for Dermatomycosis by Administration Route - Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 312: Africa Historic Review for Dermatomycosis by Administration Route - Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 313: Africa 16-Year Perspective for Dermatomycosis by Administration Route - Percentage Breakdown of Value Sales for Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration for the Years 2014, 2025 & 2030
    • TABLE 314: Africa Recent Past, Current & Future Analysis for Dermatomycosis by End-user - Hospitals End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 315: Africa Historic Review for Dermatomycosis by End-user - Hospitals End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 316: Africa 16-Year Perspective for Dermatomycosis by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제